The therapeutic efficacy of MitoQ has been investigated in mice models of diabetic kidney diseases (DKDs), where intraperitoneal administration of MitoQ reverted tubular injury by ameliorating mtROS and mitochondrial fragmentation via enhancing mitophagy mediated by Nrf2 and PTEN induced kinase 1 PINK1 [157]. Here, PINK1 is linked to diabetic kidney disease.